Rongda Xu

Bristol-Myers Squibb (United States)

Papers

1

Total Citations

87

H-Index

1

About

Rongda Xu is a leading figure in drug metabolism and pharmacokinetics (DMPK), with a career dedicated to advancing the high-throughput screening of drug candidates. His seminal work, "Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries" (2004, 87 citations), established a foundational methodology for rapidly assessing absorption, distribution, metabolism, and excretion (ADME) properties. By automating metabolic stability and CYP450 inhibition assays, Xu enabled the early elimination of compounds with poor pharmacokinetic profiles, drastically reducing late-stage drug failures. This contribution has been instrumental in shifting pharmaceutical R&D toward more efficient, data-driven lead optimization. Xu’s research has profoundly impacted the design of safer, more effective therapeutics, and his automated ADME protocols remain a gold standard in both academic and industrial labs. His work exemplifies how integrating automation with pharmacological profiling can accelerate drug discovery, making him a key innovator in the field.

Research Focus

Key Achievements

1
H-Index
1
Papers
87
Total Citations
87
Avg Citations/Paper
🏆 Most Cited Paper
Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries
87 citations · 2004
📈 Most Prolific Year: 2004 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Bristol-Myers Squibb (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago